We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Levels of Gene Variants Indicate Kidney Disease Risk

By LabMedica International staff writers
Posted on 11 Jun 2009
Three genes have been identified containing common mutations that are associated with altered kidney disease risk. More...
This discovery could lead to development of a simple blood or urine test for the gene variants to determine risk for reduced kidney function and chronic kidney disease.

Genome-wide association studies were performed on more than 20,000 people enrolled in four large population-based studies of cardiovascular disease risk factors: Atherosclerosis Risk in Communities (ARIC) Study, the Cardiovascular Health Study, the Framingham Heart Study, and the Rotterdam Study. The scientists further replicated their findings in another 20,000 participants.

Of more than 2,500,000 genetic variants that were evaluated for each study participant, the investigators found strong statistical evidence supporting three genes, UMOD (uromodulin), SHROOM3, and STC1 (stanniocalcin 1) as novel risk genes for reduced kidney function and chronic kidney disease.

One of the discovered genes, the UMOD gene, produces Tamm-Horsfall protein, the most common protein in the urine of healthy individuals. Although the Tamm-Horsfall protein has been known for almost 60 years, its functions are not well understood and its relationship to chronic kidney disease risk was not known previously.

"We have known for a long time that a higher level of proteins, such as albumin, which aren't usually present in urine, is a risk factor for kidney disease and its progression. The UMOD finding suggests that Tamm-Horsfall protein, which is thought to be a normal part of the urine, deserves attention since its genetic variation relates to risk. For all three genes, the findings are novel and suggest brand new areas for investigation including the need for developing methods to measure levels in urine or blood," said Josef Coresh, M.D., Ph.D., M.H.S., professor in the Johns Hopkins Bloomberg School of Public Health departments of epidemiology and biostatistics (Baltimore, MD, USA), and the senior Johns Hopkins author on the study.

The findings were published in the May 10, 2009 issue of the journal Nature Genetics.

More than 20 million adults in the United States alone have chronic kidney disease characterized by reduced kidney function or kidney damage. The progression of chronic kidney disease can lead to kidney failure and the need for dialysis or transplantation. In addition, chronic kidney disease increases the risk of cardiovascular diseases, mortality, and medication side effects.

Related Links:

Johns Hopkins Bloomberg School of Public Health




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: WashU Medicine researchers found that dozens of blood proteins shift during Alzheimer’s treatment and may help monitor the effects of the medication. (Image Credit: Matt Miller/WashU Medicine)

Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment

Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.